Rossari Biotech Limited (ROSSARI) — Announcement | 24 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Rossari Biotech reports 28% YoY revenue growth and record EBITDA in Q1 FY27
🔄 What Changed
EBITDA margin improved to 11.6% and PAT grew 4.5% YoY
🔮 What's Next
Target 15%+ EBITDA margins in 2-3 years; FY27 revenue growth expected to exceed 15%
💡 Investor Takeaway
Shareholders benefit from strong operational execution, margin expansion, and strategic repositioning toward high-growth segments.

Rossari Biotech reported record Q1 FY27 revenue of Rs 697.2 crore, up 28% YoY, driven by strong B2B demand and international expansion, with EBITDA rising 18.7% to Rs 80.6 crore at 11.6% margin. PAT grew 4.5% to Rs 35.1 crore, supported by portfolio rationalization and capacity utilization improvements. Management highlighted ongoing cost optimization, new high-margin product launches, and strategic CAPEX in Thailand and Saudi Arabia to target 15%+ EBITDA margins within 2-3 years. Export revenue remains stable at 23-25% of total, though freight cost inflation and raw material volatility pose near-term headwinds. The company is exiting low-margin segments and investing in higher-value applications like pharma and personal care to sustain growth momentum.

📄 View Original Announcement (PDF)

About Rossari Biotech Limited (ROSSARI)

Chemicals · Chemicals · Listed on NSE

Market Cap: ₹2,689.26 Cr P/E: 17.8 ROE: 11.3% ROCE: 13.7% Div Yield: 0.10%

View full ROSSARI stock details →

📡 Get AI alerts when ROSSARI files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ROSSARI — Free

📊 More ROSSARI filings

See all ROSSARI filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ROSSARI files new disclosures

Track ROSSARI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ROSSARI — Free

Free account · 2 AI queries/day